Fibrosis represents a response to chronic injury, aimed at maintaining organ integrity. Hepatic fibrosis is mainly related to chronic viral hepatitis B or C (HBV or HCV), alcoholic and nonalcoholic steatohepatitis (NASH), and biliary diseases. A deep understanding of the cellular and molecular mechanisms underlying liver fibrosis has enabled the development of 'pathogenetic tailored' therapeutic interventions. However, effective drugs to prevent or revert hepatic fibrosis are still lacking. In this review, we discuss the cellular populations and the molecular pathways involved in liver fibrogenesis as well as the novel approaches currently being tested in clinical trials.
|Titolo:||Emerging therapeutic targets for the treatment of hepatic fibrosis|
|Data di pubblicazione:||2016|
|Citazione:||Emerging therapeutic targets for the treatment of hepatic fibrosis / Fagone P.; Mangano K.; Pesce A.; Portale T.R.; Puleo S.; Nicoletti F.. - In: DRUG DISCOVERY TODAY. - ISSN 1359-6446. - 21:2(2016), pp. 1-9.|
|Appare nelle tipologie:||1.1 Articolo in rivista|